Allogene Therapeutics, Inc. (ALLO) vs Oculis Holding AG (OCS)
A side-by-side comparison of Allogene Therapeutics, Inc. and Oculis Holding AG across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALLO
Allogene Therapeutics, Inc.
$1.45HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
OCS
Oculis Holding AG
$8.66HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — ALLO vs OCS
growth of $100 · dividends reinvested · last 5yALLO -94.5% (-44.1%/yr)OCS -11.8% (-2.5%/yr)OCS compounded faster over this window
Log scale — wide-divergence pair
ALLO OCS
ALLO vs OCS: by the numbers
- •ALLO is the larger company ($501M vs $495M market cap).
- •Both run net losses; ALLO's is the smaller (-3566.68% vs -32724.20% net margin).
Metrics side by side
Valuation
| Metric | ALLO | OCS |
|---|---|---|
| P/S ratio | 108.00 | 1622.78 |
| P/B ratio | 1.15 | 1.82 |
Profitability
| Metric | ALLO | OCS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | -3566.68% | -32724.20% |
| ROE | -37.94% | -36.79% |
| ROIC | -34.79% | -39.63% |
Growth (annualized)
| Metric | ALLO | OCS |
|---|---|---|
| Revenue CAGR (5Y) | -34.47% | N/A |
| Total return CAGR (5Y) | -42.72% | -2.41% |
Frequently asked
- How have ALLO and OCS total returns compared?
- Over the past 5 years, ALLO delivered -42.72% and OCS delivered -2.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.